The latest international news, analysis and features on the HIV epidemic from AVERT. Share your views and expertise with your peers in the comments box below the articles.
A US trial among 15 to 17 year-old men who have sex with men (MSM) suggests this group stands to benefit hugely should pre-exposure prophylaxis (PrEP) be approved – and supported – for this age group.
Disturbing patterns of mistreatment, discrimination, violence and harassment, with knock-on impacts on health and HIV risk, have been revealed by the largest ever survey of transgender people living in the United States of America (USA).
As prescription opioid addiction continues to increase in the USA – researchers predict a rising epidemic of injecting-related diseases such as HIV and hepatitis.
As news hits that the USA is to open up its first safer injecting facility – where else in the world do they exist and why are they important for improving health outcomes?
Injecting drug use accounted for 9% of all new HIV infections in the USA in 2014 – but new demographic trends among people who inject drugs present new challenges for the HIV response.
Authorities in the Czech Republic have dropped their case against 30 HIV-positive gay men accused of having unprotected sex and spreading HIV – a criminal offence in the country.
The world’s largest drug consumption facility has opened in Copenhagen, Denmark, giving people who use drugs a safe place to use illicit substances in a way that will limit harm to themselves, and to those around them.
The UK High Court has today ruled that the National Health Service (NHS) England can legally provide the game-changing HIV prevention drug, Truvada, as a pre-exposure prophylaxis (PrEP) to HIV negative people most at risk of HIV – but only if it chooses to.
Prevalence of hepatitis C (HCV) among people who inject drugs in Europe is very high – in excess of 50% across six countries in the region and an estimated 84% in Portugal. But a new report released by EU drug body for World Hepatitis Day (July 28), shows that a combination of new treatments and prevention interventions gives significant reason for optimism in curbing the HCV epidemic among drug users in the region.
An injectable version of the opiate substitution treatment (OST) buprenorphine – which is delivered through an implant – has been approved for use in the USA by the Food and Drug Administration (FDA).